Clinical trials
Phase 2 Weight Loss trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
81 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 4 |
| 2005 | 7 |
| 2006 | 2 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 3 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 9 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 55 |
| Recruiting | 10 |
| Terminated | 6 |
| Withdrawn | 5 |
| Active, not recruiting | 4 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 5 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 5 |
| Pfizer | 4 |
| AstraZeneca | 3 |
| Avera McKennan Hospital & University Health Center | 3 |
| Christopher Bell | 2 |
| Eisai Inc. | 2 |
| Eli Lilly and Company | 2 |
| Icahn School of Medicine at Mount Sinai | 2 |
| Kaiser Permanente | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Weight Loss | 81 |
| Obesity | 55 |
| Overweight | 23 |
| Anorexia | 8 |
| Cachexia | 6 |
| Diabetes Mellitus, Type 2 | 4 |
| Colorectal Neoplasms | 3 |
| Neoplasms | 3 |
| Obesity, Morbid | 3 |
| Pancreatic Neoplasms | 3 |
Trials
Showing 1 to 25 of 81. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.